Shirley Muniz Machado Rodrigues

Dr. Shirley Muniz Machado Rodrigues


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2024 in Molecules
Verified
Journal Article
Open access
PDF file
NANaeem Asad
Naeem Asad
MLMichael Lyons
Michael Lyons
SRShirley Muniz Machado Rodrigues
Shirley Muniz Machado Rodrigues
JBJustina Burns
Justina Burns
TRThomas Roper
Thomas Roper
LJLimei Jin
Limei Jin
7-Bromo-4-chloro-1H-indazol-3-amine is a heterocyclic fragment used in the synthesis of Lenacapavir, a potent capsid inhibitor for the treatment of HIV-1 infections. In this manuscript, we describe a new approach to synthesizing 7-bromo-4-chloro-1H-indazol-3-amine from inexpensive 2,6-dichlorobenzonitrile. This synthetic method utilizes a two-step sequence including regioselective bromination and heterocycle formation with hydrazine to give the desired product in an overall isolated yield of 38–45%. The new protocol has been successfully demonstrated on hundred-gram scales without the need for column chromatography purification. This new synthesis provides a potential economical route to the large-scale production of this heterocyclic fragment of Lenacapavir.

30 April 2024 in ChemRxiv
Verified
Preprint
Open access
PDF file
NANaeem Asad
Naeem Asad
MLMichael Lyons
Michael Lyons
SRShirley Muniz Machado Rodrigues
Shirley Muniz Machado Rodrigues
JBJustina Burns
Justina Burns
TRThomas Roper
Thomas Roper
LJLimei Jin
Limei Jin
7-Bromo-4-chloro-1H-indazol-3-amine is a heterocyclic fragment used in the synthesis of Lenacapavir, a potent capsid inhibitor for the treatment of HIV-1 infections. In this manuscript, we describe a new approach to synthesizing 7-bromo-4-chloro-1H-indazol-3-amine from inexpensive 2,6-dichlorobenzonitrile. This synthetic method utilizes a two-step sequence including a regioselective bromination and heterocycle formation with hydrazine to give the desired product in an overall isolated yield of 38-45%. The new protocol has been successfully demonstrated on hundred-gram scales without the need of column chromatography purifications. This new synthesis provides a potential economical route to large scale production of this heterocyclic fragment of Lenacapavir.